No records
|
643 |
Bangun K., Halim J., Tania V. |
36902624600;57219398869;57394760300; |
Repair of Protruding Bilateral Cleft Lip and Palate With Staged Premaxilla Setback Osteotomy, Cheiloplasty, and Palatoplasty in Trisomy 17p Patient: A Review of Syndromic Clinical Characteristic |
2021 |
Cleft Palate-Craniofacial Journal |
|
|
|
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85122134129&doi=10.1177%2f10556656211069820&partnerID=40&md5=065c5cf3acef75c03e60e1e90acf33a2 |
Cleft and Craniofacial Center, Cipto Mangunkusumo General Hospital, Jakarta, Indonesia; Division of Plastic Reconstructive and Aesthetic Surgery, Department of Surgery, Faculty of Medicine Universitas Indonesia, Indonesia |
Bangun, K., Cleft and Craniofacial Center, Cipto Mangunkusumo General Hospital, Jakarta, Indonesia, Division of Plastic Reconstructive and Aesthetic Surgery, Department of Surgery, Faculty of Medicine Universitas Indonesia, Indonesia; Halim, J., Cleft and Craniofacial Center, Cipto Mangunkusumo General Hospital, Jakarta, Indonesia, Division of Plastic Reconstructive and Aesthetic Surgery, Department of Surgery, Faculty of Medicine Universitas Indonesia, Indonesia; Tania, V., Cleft and Craniofacial Center, Cipto Mangunkusumo General Hospital, Jakarta, Indonesia, Division of Plastic Reconstructive and Aesthetic Surgery, Department of Surgery, Faculty of Medicine Universitas Indonesia, Indonesia |
Objective : Chromosome 17 duplication is correlated with an increased risk of developmental delay, birth defects, and intellectual disability. Here, we reported a female patient with trisomy 17 on the whole short arm with bilateral complete cleft lip and palate (BCLP). This study will review the surgical strategies to reconstruct the protruding premaxillary segment, cleft lip, and palate in trisomy 17p patient. Case Presentation : The patient had heterozygous pathogenic duplication of chromosomal region chr17:526-18777088 on almost the entire short arm of chromosome 17. Beside the commonly found features of trisomy 17p, the patient also presented with BCLP with a prominent premaxillary portion. Premaxillary setback surgery was first performed concomitantly with cheiloplasty. The ostectomy was performed posterior to the vomero-premaxillary suture (VPS). The premaxilla was firmly adhered to the lateral segment and the viability of philtral flap was not compromised. Two-flap palatoplasty with modified intravelar veloplasty (IVV) was performed 4 months after. Conclusion : Successful positioning of the premaxilla segment, satisfactory lip aesthetics, and vital palatal flap was obtained from premaxillary setback, primary cheiloplasty, and subsequent palatoplasty in our trisomy 17p patient presenting with BLCP. Postoperative premaxillary stability and patency of the philtral and palatal flap were achieved. Longer follow-up is needed to evaluate the long-term effects of our surgical techniques on inhibition of midfacial growth. However, the benefits that the patient received from the surgery in improving feeding capacity and facial appearance early in life outweigh the cost of possible maxillary retrusion. © 2021, American Cleft Palate-Craniofacial Association. |
bilateral cleft lip and palate; premaxillary osteotomy; trisomy 17 |
|
SAGE Publications Ltd |
10556656 |
|
|
Review |
Q2 |
641 |
7859 |
|
|
645 |
Kusmardi K., Azzahra Baihaqi L., Estuningtyas A., Sahar N., Sunaryo H., Tedjo A. |
56966625300;57383198200;55650360200;57212464367;57214674652;57189320451; |
Ethanol Extract of Pomegranate (Punica granatum) Peel in Increasing the Expression of Caspase-3 in DSS-Induced Mice |
2021 |
International Journal of Inflammation |
2021 |
|
4919410 |
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85121616606&doi=10.1155%2f2021%2f4919410&partnerID=40&md5=f0575e8e8aafbe4434f9cad30aeabaca |
Department of Anatomic Pathology, Faculty of Medicine, Universitas Indonesia, Jl. Salemba Raya 6, Jakarta, Indonesia; Drug Development Research Center (DDRC Cluster, IMERI, Faculty of Medicine), Jakarta, Indonesia; Human Cancer Research Center (HCRC Cluster, IMERI, Faculty of Medicine), Universitas Indonesia, Jl. Salemba Raya 6, Jakarta, Indonesia; Faculty of Medicine, Universitas Indonesia, Jl. Salemba Raya 6, Jakarta, Indonesia; Department of Pharmacology and Therapeutic, Faculty of Medicine, Universitas Indonesia, Jl. Salemba Raya 6, Jakarta, Indonesia; Department of Biology, Faculty of Medicine, Universitas Indonesia, Jl. Salemba Raya 6, Jakarta, Indonesia; Faculty of Pharmacy and Sciences, Universitas Muhammadiyah Prof. HAMKA, Jakarta, Indonesia; Department of Medical Chemistry, Faculty of Medicine, Universitas Indonesia, Jl. Salemba Raya 6, Jakarta, Indonesia |
Kusmardi, K., Department of Anatomic Pathology, Faculty of Medicine, Universitas Indonesia, Jl. Salemba Raya 6, Jakarta, Indonesia, Drug Development Research Center (DDRC Cluster, IMERI, Faculty of Medicine), Jakarta, Indonesia, Human Cancer Research Center (HCRC Cluster, IMERI, Faculty of Medicine), Universitas Indonesia, Jl. Salemba Raya 6, Jakarta, Indonesia; Azzahra Baihaqi, L., Faculty of Medicine, Universitas Indonesia, Jl. Salemba Raya 6, Jakarta, Indonesia; Estuningtyas, A., Department of Pharmacology and Therapeutic, Faculty of Medicine, Universitas Indonesia, Jl. Salemba Raya 6, Jakarta, Indonesia; Sahar, N., Department of Biology, Faculty of Medicine, Universitas Indonesia, Jl. Salemba Raya 6, Jakarta, Indonesia; Sunaryo, H., Faculty of Pharmacy and Sciences, Universitas Muhammadiyah Prof. HAMKA, Jakarta, Indonesia; Tedjo, A., Drug Development Research Center (DDRC Cluster, IMERI, Faculty of Medicine), Jakarta, Indonesia, Department of Medical Chemistry, Faculty of Medicine, Universitas Indonesia, Jl. Salemba Raya 6, Jakarta, Indonesia |
Background. Colorectal cancer (CRC) is a malignancy derived from the glandular epithelial cells in the colon. Patients with inflammatory bowel disease (IBD) are more likely to develop CRC. Cancer proliferation is characterized by the loss of inhibition of apoptosis, which involves caspase-3 activation. This study examined the effects of the pomegranate peel extract on the expression of caspase-3 in mice crypt cells induced by dextran sodium sulfate (DSS) 2%. Methods. The experimental study was done in six groups. All treatments were done in 42 days. The groups were all induced by DSS through water drinking, except for the normal group, which was only given water. The treatments given included the pomegranate extract in two doses (240 mg and 480 mg/kg bw/day), aspirin, and ellagic acid. The specimens were then fixated and stained for the immunohistochemistry scoring for the expression of caspase-3, which was then analyzed statistically. Results. The H-scores of each treatment group were 213.23 ± 8.32 (DSS group), 243.81 ± 18.69 (normal group), 226.10 ± 12.38 (pomegranate peel extract of 240 mg/kg/d), 238.84 ± 15.81 (pomegranate peel extract of 480 mg/kg/d), 227.47 ± 12.15 (aspirin), and 224.01 ± 18.39 (ellagic acid). Statistical differences were found in one-way analysis of variance (ANOVA) and post hoc analysis among the DSS group, normal group, and dose 2 group (pomegranate peel extract of 480 mg/kg/day). Conclusions. The ethanol extract of pomegranate was able to induce apoptosis, which was demonstrated by the increase of caspase-3 expression. © 2021 Kusmardi Kusmardi et al. |
|
|
Hindawi Limited |
20908040 |
|
|
Article |
Q2 |
1106 |
3761 |
|
|
646 |
Pudjiadi A.H., Rahayu T., Wijaya S., Alatas F.S. |
18435202300;57382984100;56685332700;57217150164; |
Serum NT-Pro-BNP versus Noninvasive Bedside Inotropic Index in Paediatric Shock: A Contest of Myocardial Performance in Response to Fluid Loading |
2021 |
Critical Care Research and Practice |
2021 |
|
7458186 |
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85121597881&doi=10.1155%2f2021%2f7458186&partnerID=40&md5=9e069c0f9739bfd24a6994aa20089bfc |
Department of Child Health Cipto Mangunkusumo Hospital, Faculty of Medicine, Universitas Indonesia, Kota Depok, Indonesia; Pasar Rebo Regional General Hospital, Jakarta, Indonesia |
Pudjiadi, A.H., Department of Child Health Cipto Mangunkusumo Hospital, Faculty of Medicine, Universitas Indonesia, Kota Depok, Indonesia; Rahayu, T., Pasar Rebo Regional General Hospital, Jakarta, Indonesia; Wijaya, S., Department of Child Health Cipto Mangunkusumo Hospital, Faculty of Medicine, Universitas Indonesia, Kota Depok, Indonesia; Alatas, F.S., Department of Child Health Cipto Mangunkusumo Hospital, Faculty of Medicine, Universitas Indonesia, Kota Depok, Indonesia |
Background. Mild elevation of serum amino-terminal pro-B-type natriuretic peptide (NT-pro-BNP) is associated with myocardial dysfunction. A significantly lower Smith-Madigan inotropic index (SMII) has been shown to accurately represent cardiac contractility among heart failure subjects. We aim to monitor the effect of fluid resuscitation on cardiac function among paediatric patients by measuring serum NT-pro-BNP and SMII. Methods. This is an observational study on 70 paediatric shock patients. NT-pro-BNP and noninvasive bedside haemodynamic monitoring were done by using an ultrasonic cardiac output monitor (USCOM, USCOM, Sydney, Australia). The presence of cardiac diseases was excluded. SMII was obtained from the USCOM. An increase in the stroke volume index (SVI) of ≥15% indicates fluid responders. Measurements were taken before and after fluid loading. Results. Preloading NT-pro-BNP and SMII category were significantly different between the fluid responsiveness group, p=0.001 and p=0.004, respectively. Higher median NT-pro-BNP (preloading NT-pro-BNP of 1175.00 (254.50-9965.00) ng/mL vs. 196.00 (65.00-509.00) ng/mL, p=0.002) was associated with fluid nonresponders (subjects >12 months old). Preloading NT-pro-BNP <242.5 ng/mL was associated with fluid responders (AUC: 0.768 (0.615-0.921), p=0.003), 82.1% sensitivity, and 68.7% specificity for subjects >12 years old. Delta NT-pro-BNP in fluid responders (15.00 (-16.00-950.00) ng/mL) did not differ from fluid nonresponders (505.00 (-797.00-1600.00) ng/mL), p=0.456. Postloading SMII >1.25 W·m-2 was associated with fluid responders (AUC: 0.683 (0.553-0.813), p = 0.011), 61.9% sensitivity, and 66.7% specificity, but not preloading SMII. Fluid responders had a higher mean postloading SMII compared to nonresponders (1.36 ± 0.38 vs. 1.10 ± 0.34, p=0.006). Conclusion. Higher NT-pro-BNP and lower SMII in the absence of cardiac diseases were associated with poor response to fluid loading. The SMII is affected by low preload conditions. © 2021 Antonius Hocky Pudjiadi et al. |
|
|
Hindawi Limited |
20901305 |
|
|
Article |
Q2 |
532 |
9497 |
|
|
647 |
Carragher N., Billieux J., Bowden-Jones H., Achab S., Potenza M.N., Rumpf H.-J., Long J., Demetrovics Z., Gentile D., Hodgins D., Aricak O.T., Baigent M., Gandin C., Rahimi-Movaghar A., Scafato E., Assanangkornchai S., Siste K., Hao W., King D.L., Saunders J., Higuchi S., Poznyak V. |
24467456900;57220421868;15834239200;43860942100;7006591634;7004528536;57190689045;55882733400;7004297104;7006685175;22033598100;6602225637;7004229411;8696686900;55644049900;6603003749;55644113100;57226152467;57214845145;7402341830;57383866600;57206524465; |
Brief overview of the WHO Collaborative Project on the Development of New International Screening and Diagnostic Instruments for Gaming Disorder and Gambling Disorder |
2021 |
Addiction |
|
|
|
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85121573160&doi=10.1111%2fadd.15780&partnerID=40&md5=e4d9f85cf6d05ef0bbd42cad79ab7617 |
Alcohol, Drugs and Addictive Behaviours Unit, Department of Mental Health and Substance Use, World Health Organization, Geneva, Switzerland; National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia; Institute of Psychology, University of Lausanne, Lausanne, Switzerland; Centre for Excessive Gambling, Addiction Medicine, Lausanne University Hospitals (CHUV), Lausanne, Switzerland; National Problem Gambling Clinic; National Centre for Gaming Disorders, United Kingdom; Faculty of Brain Sciences, University College London, London, United Kingdom; WHO Collaborating Centre in Research and Training in Mental Health, Faculty of Medicine, University of Geneva, Geneva, 1202, Switzerland; Treatment Facility for Addictive Behaviors, Department of Psychiatry, University Hospitals of Geneva, Switzerland; Department of Psychiatry and Neuroscience, Child Study Center, School of Medicine, Yale University, New Haven, CT, United States; Department of Psychiatry and Psychotherapy, University of Lübeck, Germany; Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, China; Psychological Science Research Institute, Université Catholique de Louvain, Louvain-la-Neuve, Belgium; Centre of Excellence in Responsible Gaming, University of Gibraltar, Gibraltar; Addiction Research Group, ELTE Eötvös Loránd University, Budapest, Hungary; Department of Psychology, Iowa State University, Ames, IA, United States; Department of Psychology, University of Calgary, Calgary, Canada; Hasan Kalyoncu University, Gaziantep, Turkey; Turkish Green Crescent Society, Istanbul, Turkey; Department of Psychiatry, College of Medicine and Public Health, Flinders University, Adelaide, Australia; Statewide Gambling Therapy Service, Flinders Medical Centre, Bedford Park, Australia; National Observatory on Alcohol, National Institute of Health, Rome, Italy; Iranian National Center for Addiction Studies, Tehran University of Medical Sciences, Tehran, Iran; Department of Epidemiology, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand; Department of Psychiatry, Faculty of Medicine Universitas Indonesia, dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia; Mental Health Institute of the Second Xiangya Hospital, Central South University, China; Consortium on Clinical bigdata and Biobank for Addiction Research (3CBAR), Changsha, Hunan, China; College of Education, Psychology, and Social Work, Flinders University, Australia; Department of Public Health Sciences, University of Connecticut School of Medicine, University of Queensland, Australia; National Hospital Organization Kurihama Medical and Addiction Center, Japan |
Carragher, N., Alcohol, Drugs and Addictive Behaviours Unit, Department of Mental Health and Substance Use, World Health Organization, Geneva, Switzerland, National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia; Billieux, J., Institute of Psychology, University of Lausanne, Lausanne, Switzerland, Centre for Excessive Gambling, Addiction Medicine, Lausanne University Hospitals (CHUV), Lausanne, Switzerland; Bowden-Jones, H., National Problem Gambling Clinic; National Centre for Gaming Disorders, United Kingdom, Faculty of Brain Sciences, University College London, London, United Kingdom; Achab, S., WHO Collaborating Centre in Research and Training in Mental Health, Faculty of Medicine, University of Geneva, Geneva, 1202, Switzerland, Treatment Facility for Addictive Behaviors, Department of Psychiatry, University Hospitals of Geneva, Switzerland; Potenza, M.N., Department of Psychiatry and Neuroscience, Child Study Center, School of Medicine, Yale University, New Haven, CT, United States; Rumpf, H.-J., Department of Psychiatry and Psychotherapy, University of Lübeck, Germany; Long, J., Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, China, Psychological Science Research Institute, Université Catholique de Louvain, Louvain-la-Neuve, Belgium; Demetrovics, Z., Centre of Excellence in Responsible Gaming, University of Gibraltar, Gibraltar, Addiction Research Group, ELTE Eötvös Loránd University, Budapest, Hungary; Gentile, D., Department of Psychology, Iowa State University, Ames, IA, United States; Hodgins, D., Department of Psychology, University of Calgary, Calgary, Canada; Aricak, O.T., Hasan Kalyoncu University, Gaziantep, Turkey, Turkish Green Crescent Society, Istanbul, Turkey; Baigent, M., Department of Psychiatry, College of Medicine and Public Health, Flinders University, Adelaide, Australia, Statewide Gambling Therapy Service, Flinders Medical Centre, Bedford Park, Australia; Gandin, C., National Observatory on Alcohol, National Institute of Health, Rome, Italy; Rahimi-Movaghar, A., Iranian National Center for Addiction Studies, Tehran University of Medical Sciences, Tehran, Iran; Scafato, E., National Observatory on Alcohol, National Institute of Health, Rome, Italy; Assanangkornchai, S., Department of Epidemiology, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand; Siste, K., Department of Psychiatry, Faculty of Medicine Universitas Indonesia, dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia; Hao, W., Mental Health Institute of the Second Xiangya Hospital, Central South University, China, Consortium on Clinical bigdata and Biobank for Addiction Research (3CBAR), Changsha, Hunan, China; King, D.L., College of Education, Psychology, and Social Work, Flinders University, Australia; Saunders, J., Department of Public Health Sciences, University of Connecticut School of Medicine, University of Queensland, Australia; Higuchi, S., National Hospital Organization Kurihama Medical and Addiction Center, Japan; Poznyak, V., Alcohol, Drugs and Addictive Behaviours Unit, Department of Mental Health and Substance Use, World Health Organization, Geneva, Switzerland |
[No abstract available] |
Addictive behaviours; assessment; diagnosis; gambling; gaming; screening; video games; WHO |
|
John Wiley and Sons Inc |
09652140 |
|
|
Letter |
Q1 |
2424 |
961 |
|
|
650 |
Jufri M., Vardhani A., Purwaningsih E. |
55542805100;57372533300;57186723500; |
Evaluating the efficacy of lotion containing black rice bran (Oryza sativa L. indica) extract as skin brightening agent: A clinical trial |
2021 |
Jundishapur Journal of Natural Pharmaceutical Products |
16 |
4 |
e114152 |
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85121121214&doi=10.5812%2fjjnpp.114152&partnerID=40&md5=7475812ecd399617effa3198e4bc8700 |
Faculty of Pharmacy, Universitas Indonesia, Indonesia; Department of Pharmacy, Faculty of Medicine, Universitas Indonesia, Indonesia |
Jufri, M., Faculty of Pharmacy, Universitas Indonesia, Indonesia; Vardhani, A., Faculty of Pharmacy, Universitas Indonesia, Indonesia; Purwaningsih, E., Department of Pharmacy, Faculty of Medicine, Universitas Indonesia, Indonesia |
Background: Ultraviolet exposure is an extrinsic factor to initiate melanogenesis, the process of melanin formation in the skin. Nowadays, natural ingredients tend to be more prevalent in cosmetic formulations due to consumers’ concern about synthetic ingredients and the risks they may represent for human health. Rice bran, the outer layer of a rice grain, can be utilized as a skin-lightening agent. Objectives: This study aimed to determine the efficacy of a lotion containing black rice bran (Oryza sativa L. indica) ethanolic extract as a skin lightening agent. Methods: The black rice bran ethanolic extract was formulated into oil in water (o/w) lotion. In this study, 34 women applied the lotion at one side of the forearm and base placebo lotion as control at the other side of forearm. The results were tested with a paired t-test by GraphPad Prism 8.3.0 software. Results: There was a significant decrease in the melanin index and erythema index in the forearm with a lotion containing black rice bran extract (P-value < 0.0001). Conclusions: The lotion containing 10% black rice bran extract was effective as a skin lightener because it effectively reduced skin melanin production when applied topically. Copyright © 2021, Author(s). |
Black Rice Bran; Clinical Trials; Natural Product; Oryza sativa L. indica; Skin Lightening Agent |
|
Kowsar Medical Institute |
17357780 |
|
|
Article |
Q3 |
228 |
17746 |
|
|
655 |
Ota N., Yoshimoto Y., Darwis N.D.M., Sato H., Ando K., Oike T., Ohno T. |
57359393800;36453407100;57200045716;55697961900;55641963900;36453136000;35395665700; |
High tumor mutational burden predicts worse prognosis for cervical cancer treated with radiotherapy |
2021 |
Japanese Journal of Radiology |
|
|
|
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85120410945&doi=10.1007%2fs11604-021-01230-5&partnerID=40&md5=4f3db9b90e6b959382e2d0ca7b994c0b |
Department of Radiation Oncology, Gunma University Graduate School of Medicine, 3-39-22, Showa-machi, Maebashi, Gunma 371-8511, Japan; Department of Radiation Oncology, School of Medicine, Fukushima Medical University, 1, Hikarigaoka, Fukushima, 960-1295, Japan; Department of Radiation Oncology, Faculty of Medicine Universitas Indonesia, Dr. Cipto Mangunkusumo National General Hospital, Jl. Diponegoro No. 71, Jakarta Pusat, DKI Jakarta 10430, Indonesia; Gunma University Heavy Ion Medical Center, 3-39-22, Showa-machi, Maebashi, Gunma 371-8511, Japan |
Ota, N., Department of Radiation Oncology, Gunma University Graduate School of Medicine, 3-39-22, Showa-machi, Maebashi, Gunma 371-8511, Japan; Yoshimoto, Y., Department of Radiation Oncology, Gunma University Graduate School of Medicine, 3-39-22, Showa-machi, Maebashi, Gunma 371-8511, Japan, Department of Radiation Oncology, School of Medicine, Fukushima Medical University, 1, Hikarigaoka, Fukushima, 960-1295, Japan; Darwis, N.D.M., Department of Radiation Oncology, Gunma University Graduate School of Medicine, 3-39-22, Showa-machi, Maebashi, Gunma 371-8511, Japan, Department of Radiation Oncology, Faculty of Medicine Universitas Indonesia, Dr. Cipto Mangunkusumo National General Hospital, Jl. Diponegoro No. 71, Jakarta Pusat, DKI Jakarta 10430, Indonesia; Sato, H., Gunma University Heavy Ion Medical Center, 3-39-22, Showa-machi, Maebashi, Gunma 371-8511, Japan; Ando, K., Department of Radiation Oncology, Gunma University Graduate School of Medicine, 3-39-22, Showa-machi, Maebashi, Gunma 371-8511, Japan; Oike, T., Department of Radiation Oncology, Gunma University Graduate School of Medicine, 3-39-22, Showa-machi, Maebashi, Gunma 371-8511, Japan, Gunma University Heavy Ion Medical Center, 3-39-22, Showa-machi, Maebashi, Gunma 371-8511, Japan; Ohno, T., Department of Radiation Oncology, Gunma University Graduate School of Medicine, 3-39-22, Showa-machi, Maebashi, Gunma 371-8511, Japan, Gunma University Heavy Ion Medical Center, 3-39-22, Showa-machi, Maebashi, Gunma 371-8511, Japan |
Purpose: Tumor mutational burden (TMB) is a surrogate biomarker of neo-antigens and high TMB status is associated with favorable response to immune-checkpoint inhibitors (ICIs). This study aimed to elucidate the association between TMB and the outcome of definitive radiotherapy in patients with cervical cancer. Materials and methods: TMB and treatment outcome were retrospectively analyzed in patients with newly diagnosed cervical cancer treated with definitive radiotherapy available with somatic mutation data of pre-treatment tumors obtained using a commercially available gene panel. Results: The study enrolled 98 patients (median follow-up period, 61 months). The median TMB was 9.5 mutations per megabase (range, 3.0–35.5 mutations per megabase). After dichotomization based on this median value, the 5-year overall survival (OS) for TMB-high patients was significantly worse than that of TMB-low patients (61.1% vs. 82.2%). Multivariate analysis identified high TMB status as a significant prognostic factor for worse OS, along with advanced stage, para-aortic lymph node involvement, and absence of concurrent chemotherapy. Conclusion: These data indicate that TMB is a potential prognostic factor for worse survival in patients with cervical cancer treated with definitive radiotherapy, thereby providing a rationale for treatment of TMB-high cervical cancers with a combination of ICIs plus radiotherapy. Secondary abstract: This retrospective study of 98 patients demonstrates for the first time that tumor mutational burden (TMB) is an independent prognostic factor for worse overall survival of patients treated with definitive radiotherapy, providing a rationale for treatment of TMB-high cervical cancers with a combination of immune-checkpoint inhibitors plus radiotherapy. © 2021, The Author(s). |
Cervical cancer; Prognosis; Radiotherapy; Tumor mutational burden |
|
Springer Japan |
18671071 |
|
|
Article |
Q2 |
616 |
8208 |
|
|
656 |
Marwali E.M., Lopolisa A., Sani A.A., Rayhan M., Roebiono P.S., Fakhri D., Haas N.A., Slee A., Portman M.A. |
36608535400;57358496100;57209881028;57219904946;57192895321;8599513100;7103216848;7004895873;7004985824; |
Indonesian Study: Triiodothyronine for Infants Less than 5 Months Undergoing Cardiopulmonary Bypass |
2021 |
Pediatric Cardiology |
|
|
|
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85120384775&doi=10.1007%2fs00246-021-02779-8&partnerID=40&md5=ee32a32dc863edb4c293caf61a4c9fea |
Pediatric Cardiac Intensive Care Unit, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia; Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Pediatric Cardiology Unit, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia; Pediatric Cardiac Surgery Unit, National Cardiovascular Center Harapan Kita, Department of Cardiothoracic Vascular Surgery, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Department of Pediatric Cardiology and Pediatric Intensive Care, Medical Hospital of the University of Munich, Munich, Germany; Axio Research, Seattle Children’s Hospital and Research Institute, Seattle, United States; Seattle Children’s Hospital, University of Washington, Seattle, WA, United States; National Cardiovascular Center Harapan Kita, Jl. Let. Jend. S. Parman, Kav 87, Slipi, West Jakarta 11420, Indonesia |
Marwali, E.M., Pediatric Cardiac Intensive Care Unit, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia, Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia, National Cardiovascular Center Harapan Kita, Jl. Let. Jend. S. Parman, Kav 87, Slipi, West Jakarta 11420, Indonesia; Lopolisa, A., Pediatric Cardiac Intensive Care Unit, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia; Sani, A.A., Pediatric Cardiac Intensive Care Unit, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia; Rayhan, M., Pediatric Cardiac Intensive Care Unit, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia; Roebiono, P.S., Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia, Pediatric Cardiology Unit, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia; Fakhri, D., Pediatric Cardiac Surgery Unit, National Cardiovascular Center Harapan Kita, Department of Cardiothoracic Vascular Surgery, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Haas, N.A., Department of Pediatric Cardiology and Pediatric Intensive Care, Medical Hospital of the University of Munich, Munich, Germany; Slee, A., Axio Research, Seattle Children’s Hospital and Research Institute, Seattle, United States; Portman, M.A., Seattle Children’s Hospital, University of Washington, Seattle, WA, United States |
This study evaluates the efficacy and safety of oral triiodothyronine on time to extubation for infants less than 5 months undergoing heart surgery in Indonesia, and primarily relates to patients in emerging programs with high malnutrition and mortality. In this randomized, double-blind, placebo-controlled trial, oral triiodothyronine (T3, Tetronine®) 1 μg/kg-body weight/dose or placebo (saccharum lactis) was administered via nasogastric tube every 6 h for 60 h to treatment group. A total of 120 patients were randomized into T3 (61 patients) and placebo (59 patients) groups. The majority of the patients had moderate to severe malnutrition (55.83%) with a high post-operative mortality rate of 23.3%. The T3 group showed significantly higher serum FT3 levels from 1 until 48 h post cross-clamp removal (p < 0.0001), lower incidence of low cardiac output syndrome at both 6 h (28 [45.9%] vs. 39 [66.1%] patients, p = 0.03, OR 2.3, 95% CI: 1.10–4.81) and 12 h after cross-clamp removal (25 [41.7%] vs. 36 [63.2%], p = 0.02, OR 2.40, 95% CI: 1.14–5.05). Although not statistically significant, the treatment group had shorter median (IQR) intubation time (2.59 [1.25–5.24] vs. 3.77 [1.28–6.64] days, p = 0.16, HR 1.36, 95% CI: 0.88–2.09)] and lower mortality (10 [16.4%] vs. 18 [30.5%], p = 0.07]. Patients with Aristotle score < 10.0 (low risk) receiving T3 had faster extubation than placebo patients (p = 0.021, HR of 1.90, 95% CI: 1.10–3.28) and were significantly less likely to require CPR or experience infection (p = 0.027, OR 8.56, 95% CI:0.99–73.9 and p = 0.022, OR 4.09 95% CI: 1.16–14.4, respectively). Oral T3 supplementation reduced overall incidence of low cardiac output syndrome and significantly reduced the time to extubation in low-risk patients. Therefore, prophylactic oral T3 administration may be beneficial in these patients. Trial Registration: ClinicalTrials.gov NCT02222532. © 2021, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. |
Congenital open cardiac surgery; Low cardiac output; Time-to-extubation; Triiodothyronine |
|
Springer |
01720643 |
|
|
Article |
Q2 |
646 |
7791 |
|
|
657 |
Irawan C., Benbella L.G., Rachman A., Mansjoer A. |
28767651600;57357413600;15056701600;24335647800; |
Factors that Influence 2-Year Progression-Free Survival Among Head and Neck Cancer Patients |
2021 |
Journal of Epidemiology and Global Health |
|
|
|
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85120335157&doi=10.1007%2fs44197-021-00016-2&partnerID=40&md5=eae0237d32c525daedf560529a50ad64 |
Hematology and Medical Oncology Division, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia-Cipto Mangunkusumo National Central General Hospital (RSCM), Jl. Diponegoro no. 71, Jakarta, 10430, Indonesia; Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia-Cipto Mangunkusumo National Central General Hospital (RSCM), Jakarta, Indonesia; Cardiology Division, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia-Cipto Mangunkusumo National Central General Hospital (RSCM), Jakarta, Indonesia |
Irawan, C., Hematology and Medical Oncology Division, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia-Cipto Mangunkusumo National Central General Hospital (RSCM), Jl. Diponegoro no. 71, Jakarta, 10430, Indonesia; Benbella, L.G., Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia-Cipto Mangunkusumo National Central General Hospital (RSCM), Jakarta, Indonesia; Rachman, A., Hematology and Medical Oncology Division, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia-Cipto Mangunkusumo National Central General Hospital (RSCM), Jl. Diponegoro no. 71, Jakarta, 10430, Indonesia; Mansjoer, A., Cardiology Division, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia-Cipto Mangunkusumo National Central General Hospital (RSCM), Jakarta, Indonesia |
Objectives: The majority of patients with head and neck cancer (HNC) come to the hospital at advanced stages. This research was conducted to determine the mortality, 2-year progression-free survival (PFS) and factors that influenced PFS of HNC patients. Methods: A retrospective cohort study was conducted among locally advanced HNC patients who underwent chemoradiation for the first time at RSCM from January 2015 to December 2017. Data were retrieved through medical records. Laboratory data were taken 2–4 weeks prior and 2–4 weeks after chemoradiation. PFS observation started from the first day of chemoradiation until disease progression or death. PFS data were recorded in two groups: ≤ 2 years and > 2 years. The Chi-square test was used for bivariate analysis with the Fischer-exact test as an alternative. Variables will be further tested using multivariate logistic regression tests. Results: Among 216 subjects, there were 103 (47.69%) patients who did not reach overall survival (OS) > 2 years. There were 108 (50%) patients who had PFS > 2 years. Based on the results of multivariate analysis, it was found that smoking, hemoglobin level ≤ 12 g/dl, ECOG (Eastern Cooperative Oncology Group) 1–2, and negative therapeutic response were associated with poor PFS. Hazard ratio (HR) for 2-year PFS for Brinkman index > 250 was 1.36 (95% CI 0.93–2.00; p = 0.02); HR for Hb ≤ 12 g/dl was 1.65 (95% CI 1.13–2.42; p = 0.01); HR for ECOG 1–2 was 4.05 (95% CI 1.49–11.00; p < 0.01); and HR for negative therapeutic response was 2.37 (95% CI 1.43–3.94; p < 0.01). Conclusion: Mortality of HNC patients within 2 years is 47.69%, with a 2-year PFS reaching 50%. Cigarette smoking, low hemoglobin levels, poor performance status, and negative therapeutic response (non-responders) negatively affect the 2-year PFS. © 2021, The Author(s). |
Factor; Head and neck cancer; Mortality; Progression-free survival |
|
Atlantis Press |
22106006 |
|
|
Article |
Q3 |
665 |
7531 |
|
|
660 |
Ramani S., McKimm J., Forrest K., Hays R., Bishop J., Thampy H., Findyartini A., Nadarajah V.D., Kusurkar R., Wilson K., Filipe H., Kachur E. |
56186462600;26433565200;26635053400;7202509928;8406026800;55349958700;56543777300;14048599600;6603461994;56926010000;36657108400;6603938626; |
Co-creating scholarship through collaborative writing in health professions education: AMEE Guide No. 143 |
2021 |
Medical Teacher |
|
|
|
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85120044813&doi=10.1080%2f0142159X.2021.1993162&partnerID=40&md5=3773bd230107ba738a15f75175eba901 |
Harvard Medical School, Boston, United States; Manchester Medical School, University of Manchester, Manchester, United Kingdom; Swansea University Medical School, United Kingdom; Bond University, Queensland, Australia; James Cook University College of Medicine and Dentistry, James Cook University, Townsville, Australia; Department of Medical Education, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; International Medical University, Kuala Lumpur, Malaysia; Amsterdam UMC, Research in Education, Faculty of Medicine, Vrije Universiteit, Amsterdam, Netherlands; Dalhousie University, Halifax, NS, Canada; Hospital Egas Moniz, West Lisbon Hospitals Center (NHS), University of Lisbon, Lisboa, Portugal; Medical Education Development, Global Consulting, New York, NY, United States |
Ramani, S., Harvard Medical School, Boston, United States, Manchester Medical School, University of Manchester, Manchester, United Kingdom; McKimm, J., Swansea University Medical School, United Kingdom; Forrest, K., Bond University, Queensland, Australia; Hays, R., James Cook University College of Medicine and Dentistry, James Cook University, Townsville, Australia; Bishop, J., Bond University, Queensland, Australia; Thampy, H., Manchester Medical School, University of Manchester, Manchester, United Kingdom; Findyartini, A., Department of Medical Education, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Nadarajah, V.D., International Medical University, Kuala Lumpur, Malaysia; Kusurkar, R., Amsterdam UMC, Research in Education, Faculty of Medicine, Vrije Universiteit, Amsterdam, Netherlands; Wilson, K., Dalhousie University, Halifax, NS, Canada; Filipe, H., Hospital Egas Moniz, West Lisbon Hospitals Center (NHS), University of Lisbon, Lisboa, Portugal; Kachur, E., Medical Education Development, Global Consulting, New York, NY, United States |
This AMEE guide provides a robust framework and practical strategies for health professions educators to enhance their writing skills and engage in successful scholarship within a collaborative writing team. Whether scholarly output involves peer-reviewed articles, book chapters, blogs and online posts, online educational resources, collaborative writing requires more than the usual core writing skills, it requires teamwork, leadership and followership, negotiation, and conflict resolution, mentoring and more. Whilst educators can attend workshops or courses to enhance their writing skills, there may be fewer opportunities to join a community of scholars and engage in successful collaborative writing. There is very little guidance on how to find, join, position oneself and contribute to a writing group. Once individuals join a group, further questions arise as to how to contribute, when and whom to ask for help, whether their contribution is significant, and how to move from the periphery to the centre of the group. The most important question of all is how to translate disparate ideas into a shared key message and articulate it clearly. In this guide, we describe the value of working within a collaborative writing group; reflect on principles that anchor the concept of writing as a team and guide team behaviours; suggest explicit strategies to overcome challenges and promote successful writing that contributes to and advances the field; and review challenges to starting, maintaining, and completing writing tasks. We approach writing through three lenses: that of the individual writer, the writing team, and the scholarly product, the ultimate goal being meaningful contributions to the field of Health Professions Education. © 2021 AMEE. |
collaborative/peer-to-peer; Continuing; leadership; mentoring; staff development |
|
Taylor and Francis Ltd. |
0142159X |
|
|
Article |
Q1 |
1355 |
2689 |
|
|
662 |
Ta J.W.C., Chew D.P., Tsui K.L., Tan D., Duplyakov D., Hammoudeh A., Zhang B., Li Y., Xu K., Ong P.J., Firman D., Gamra H., Almahmeed W., Dalal J., Tam L.-W., Steg G., Nguyen Q.N., Ako J., Al Suwaidi J., Chan M., Sobhy M., Shehab A., Buddhari W., Wang Z., Fong A.Y.Y., Karadag B., Kim B.-K., Baber U., Chin C.T., Han Y.L. |
57354736300;7102026332;7101671562;50263435900;6506125408;8088443300;56637270100;55914058500;56510776700;7102312670;54898724100;7004594521;6506558682;7004278395;56585509700;57197860836;39962151600;6701389098;6603728555;23388249600;55345664600;6603838351;57192991797;8875501800;14321654600;56243107600;35189204900;16047315200;57226594604;57211831338; |
2021 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y12 Receptor Antagonists in the Asia-Pacific Region: Special Populations |
2021 |
European Cardiology Review |
16 |
|
|
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85119968735&doi=10.15420%2fecr.2021.35&partnerID=40&md5=0f474aea7166811035b920e727476fae |
National Heart Centre, Singapore; Sengkang General Hospital, Singapore; College of Medicine and Public Health, Flinders University, Adelaide, Australia; Pamela Youde Nethersole Eastern Hospital, Hong Kong; Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore; Samara Regional Cardiology Dispensary, Samara, Russian Federation; Cardiology Department, Istishari Hospital, Amman, Jordan; Department of Cardiology, First Affiliated Hospital, Dalian Medical University, Dalian, China; Department of Cardiology, General Hospital of Northern Theatre Command, Shenyang, China; Department of Cardiology, General Hospital of Shenyang Military, Shenyang, China; Heart Specialist International, Mount Elizabeth Novena Hospital, Singapore; Tan Tock Seng Hospital, Singapore; Harapan Kita National Cardiovascular Center, Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia Harapan Kita, Jakarta, Indonesia; Cardiology Department, Fattouma Bourguiba University Hospital, University of Monastir, Monastir, Tunisia; Cleveland Clinic Abu Dhabi, United Arab Emirates; Centre for Cardiac Sciences, Kokilaben Dhirubhai Ambani Hospital, Mumbai, India; Kwong Wah Hospital, Hong Kong; Department of Cardiology, Hôpital Bichat, Paris, France; Department of Cardiology, Hanoi Medical University, Hanoi, Viet Nam; Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan; Adult Cardiology, Hamad Medical Corporation, Doha, Qatar; National University Heart Centre, Singapore; Faculty of Medicine, Alexandria University, Egypt; College of Medicine and Health Sciences, UAE University, Al Ain, United Arab Emirates; King Chulalongkorn Memorial Hospital, Bangkok, Thailand; Sarawak Heart Centre, Kota Samarahan, Malaysia; Istanbul University, Cerrahpasa School of Medicine, Istanbul, Turkey; Division of Cardiology, Department of Internal Medicine, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, South Korea; University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States |
Ta, J.W.C., National Heart Centre, Singapore, Sengkang General Hospital, Singapore; Chew, D.P., College of Medicine and Public Health, Flinders University, Adelaide, Australia; Tsui, K.L., Pamela Youde Nethersole Eastern Hospital, Hong Kong; Tan, D., Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore; Duplyakov, D., Samara Regional Cardiology Dispensary, Samara, Russian Federation; Hammoudeh, A., Cardiology Department, Istishari Hospital, Amman, Jordan; Zhang, B., Department of Cardiology, First Affiliated Hospital, Dalian Medical University, Dalian, China; Li, Y., Department of Cardiology, General Hospital of Northern Theatre Command, Shenyang, China; Xu, K., Department of Cardiology, General Hospital of Shenyang Military, Shenyang, China; Ong, P.J., Heart Specialist International, Mount Elizabeth Novena Hospital, Singapore, Tan Tock Seng Hospital, Singapore; Firman, D., Harapan Kita National Cardiovascular Center, Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia Harapan Kita, Jakarta, Indonesia; Gamra, H., Cardiology Department, Fattouma Bourguiba University Hospital, University of Monastir, Monastir, Tunisia; Almahmeed, W., Cleveland Clinic Abu Dhabi, United Arab Emirates; Dalal, J., Centre for Cardiac Sciences, Kokilaben Dhirubhai Ambani Hospital, Mumbai, India; Tam, L.-W., Kwong Wah Hospital, Hong Kong; Steg, G., Department of Cardiology, Hôpital Bichat, Paris, France; Nguyen, Q.N., Department of Cardiology, Hanoi Medical University, Hanoi, Viet Nam; Ako, J., Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan; Al Suwaidi, J., Adult Cardiology, Hamad Medical Corporation, Doha, Qatar; Chan, M., National University Heart Centre, Singapore; Sobhy, M., Faculty of Medicine, Alexandria University, Egypt; Shehab, A., College of Medicine and Health Sciences, UAE University, Al Ain, United Arab Emirates; Buddhari, W., King Chulalongkorn Memorial Hospital, Bangkok, Thailand; Wang, Z., Department of Cardiology, General Hospital of Shenyang Military, Shenyang, China; Fong, A.Y.Y., Sarawak Heart Centre, Kota Samarahan, Malaysia; Karadag, B., Istanbul University, Cerrahpasa School of Medicine, Istanbul, Turkey; Kim, B.-K., Division of Cardiology, Department of Internal Medicine, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, South Korea; Baber, U., University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States; Chin, C.T., National Heart Centre, Singapore; Han, Y.L., Department of Cardiology, General Hospital of Northern Theatre Command, Shenyang, China |
Advanced age, diabetes, and chronic kidney disease not only increase the risk for ischaemic events in chronic coronary syndromes (CCS) but also confer a high bleeding risk during antiplatelet therapy. These special populations may warrant modification of therapy, especially among Asians, who have displayed characteristics that are clinically distinct from Western patients. Previous guidance has been provided regarding the classification of high-risk CCS and the use of newer-generation P2Y12inhibitors (i.e. ticagrelor and prasugrel) after acute coronary syndromes (ACS) in Asia. The authors summarise evidence on the use of these P2Y12inhibitors during the transition from ACS to CCS and among special populations. Specifically, they present recommendations on the roles of standard dual antiplatelet therapy, shortened dual antiplatelet therapy and single antiplatelet therapy among patients with coronary artery disease, who are either transitioning from ACS to CCS; elderly; or with chronic kidney disease, diabetes, multivessel coronary artery disease and bleeding events during therapy. © 2021 Radcliffe Group Ltd. All rights reserved. |
Asia; Comorbidity; Consensus; Dual antiplatelet therapy; Myocardial ischaemia; Platelet aggregation inhibitors |
|
Radcliffe Medical Media |
17583756 |
|
|
Article |
Q2 |
864 |
5422 |
|
|